Publication: Omaveloxolone and TX63682 Are Hepatoprotective in the STAM Mouse Model of NASH

Omaveloxolone and novel Nrf2 activator TX63682 decreased hepatic fat deposition, hepatocellular ballooning, hepatic inflammatory cell infiltration, nonfasting blood glucose and glycated hemoglobin A1C concentrations, and liver and serum triglycerides in the STAM mouse model of nonalcoholic steatohepatitis (NASH).

  • Omaveloxolone and TX63682 demonstrated significant hepatoprotection in a rodent model of NASH in conjunction with improvements in glucose control and lipid handling, which is consistent with the overall phenotype of improved mitochondrial function that is associated with Nrf2 activation.
  • Mild increases in serum transaminases were observed in conjunction with improvements in hepatic histology and without major changes in serum bilirubin suggesting that they are a pharmacological and not toxic effect.
  • Overall, these data suggest that changes in serum chemistries and other blood based markers observed with our Nrf2 activators are likely a pharmacologic effect of Nrf2 activation associated with restoration of lipid metabolism and suppression of inflammation.